Sanofi Pasteur and US biotech Immune Design have agreed to pool assets in a collaboration aimed at developing a best-in-class herpes simplex virus-2 (HSV-2) vaccine. The collaboration will evaluate the potential of different combinations of agents, including Sanofi’s clinical-stage replication-defective HSV-2 vaccine, HSV-529, and Immune Design’s preclinical trivalent vaccine, G103. There is no approved therapeutic or prophylactic vaccine for HSV-2, which is the leading cause of genital herpes worldwide. Sanofi and Immune Design partnered earlier in 2014 to use Immune Design’s GLAAS™ platform to develop therapeutics for a selected food allergy.